Despite COVID-19, Expert Group Moves Ahead With Public Meeting On Pediatric Device Development

While the US FDA has been developing a framework over the past few years to address the lack of pediatric devices on the market, the agency awarded a grant to the multi-stakeholder group C-Path to continue that work at the same time that the coronavirus pandemic started. Despite the hurdles, C-Path says it is still doing its work and plans to convene a public meeting on the issue in September.

Health Care teddy bear Heart stethoscope with filter effect retro vintage style

While the ongoing COVID-19 crisis is hampering the work of many organizations, the Critical Path Institute (C-Path) says it still plans to hold a public meeting in September and is moving ahead with bringing expert stakeholders together to try to solve the longstanding problem of developing medical devices for children.

C-Path is a public-private partnership of industry, academic and government experts who tend to work on developing new approaches and guidances to help solve questions in medical product regulation and...

More from Regulation

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.